PremiumRatingsAlnylam Pharma’s Strong Market Position and Amvuttra’s Impressive Sales Growth Drive Buy Recommendation Alnylam Pharma’s Strong Commercial Momentum and Promising Pipeline Justify Buy Rating and $500 Price Target Cautious Outlook on Alnylam Pharma Amid Mixed Financial Results and Market Uncertainties PremiumCompany AnnouncementsAlnylam Pharmaceuticals Reports Strong Start to 2025 Alnylam Pharma: Strong Strategic Positioning and Growth Prospects Justify Buy Rating Alnylam Pharma: Hold Rating Amid Steady Growth and Market Uncertainties PremiumRatingsAlnylam Pharma: Hold Rating Amid EU Approval Prospects and Pricing Challenges ALNY Earnings this Week: How Will it Perform? Alnylam Pharma’s Promising Outlook in the ATTR-CM Market: A Buy Recommendation by Maury Raycroft 
